Menopause, obesity, and comorbidity: possibilities of menopausal hormone therapy

DOI

https://dx.doi.org/10.18565/aig.2019.5.43-48

Protasova A.E., Yureneva S.V., Bairamova N.N., Komedina V.I.
1) Department of Oncology, Faculty of Medicine, Saint Petersburg State University, Saint Petersburg, Russia; 2) V.A. Almazov National Medical Research Center, Ministry of Health of Russia, Saint Petersburg, Russia; 3) I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia; 4) OOO «AVA-PETER», Saint Petersburg, Russia; 5) Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

The steady increase in cancer incidence rates necessitates studies of global risk factors for cancer and a search for novel methods of effective primary prevention. According to the International Cancer Research Agency (IARC, 2017), obesity also increases the risk for development of 13 most common malignant neoplasms (MNs), including breast, colon, pancreas, bladder, and endometrial cancers; the incidence of MNs caused by overweight and obesity among women is 5.4%. Menopausal metabolic syndrome (metabolic syndrome associated with the development of hypogonadism) occurs in 40% of postmenopausal women. Menopausal hormone therapy (MHT) for women in the early postmenopause and/or those who are younger than 60 years, and overweight control reduces overall mortality from 30 to 52% and contributes to the primary prevention of a number of MNs, including breast cancer, type 2 diabetes mellitus, and cardiovascular disease. In addition to MHT, lifestyle modification should be recommended to control body weight and to increase physical activity.

menopausal hormone therapy

menopause

obesity

metabolic syndrome

breast cancer

Full text (in Russian)

The Organisation for Economic Cooperation and Development (OECD). Obesity update 2017. Available at: http://www.oecd.org/health/obesity-update.htm
ВОЗ. Вторая Международная конференция по вопросам питания. Рим, 19–21 ноября 2014 года. Итоговый документ конференции: Римская декларация по вопросам питания. [WHO. Second International Conference on Nutrition. Rome, November 19–21, 2014. Conference Outcome Document: Rome Declaration on Nutrition. (in Russian)]. Available at: http://www.fao.org/3/a-ml542r.pdf
Всемирная организация здравоохранения. Международная классификация болезней, 11 пересмотр. [World Health Organization. International Classification of Diseases, 11 revision. (in Russian)]. Available at: https://icd.who.int
Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. Cancer J. Clin. 2015; 65(2): 87-108. https://dx.doi.org/10.3322/caac.21262.
Lauby-Secretan B., Scoccianti C., Loomis D., Grosse Y., Bianchini F., Straif K.; International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer – viewpoint of the IARC Working Group. N. Engl. J. Med. 2016; 375(8): 794-8. https://dx.doi.org/10.1056/NEJMsr1606602.
Arnold M., Pandeya N., Byrnes G., Renehan P.A.G., Stevens G.A., Ezzati P.M. et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015; 16(1): 36-46. https://dx.doi.org/10.1016/S1470-2045(14)71123-4.
Roberts H., Hicke M. Managing the menopause: An update. Maturitas. 2016; 86: 53-8. https://dx.doi.org/10.1016/j.maturitas.2016.01.007.
Kapoor E., Collazo-Clavell M.L., Faubion S.S.Weight gain in women at midlife: a concise review of the pathophysiology and strategies for management. Mayo Clin. Proc. 2017; 92(10): 1552-8.
Greendale G.A., Sternfeld B., Huang M., Han W., Karvonen-Gutierrez C., Ruppert K. et al. Changes in body composition and weight during the menopause transition. JCIInsight. 2019;4(5): e124865. https://dx.doi.org/10.1172/jci.insight.124865.
Sutton-Tyrrell K., Zhao X., Santoro N., Lasley B., Sowers M., Johnston J. et al. Reproductive hormones and obesity: 9 years of observation from the Study of Women’s Health Across the Nation. Am. J. Epidemiol. 2010; 171(11): 1203-13.
Genazzani A.R., Gambacciani M. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol. Endocrinol. 2006: 22(3): 145-50. https://dx.doi.org/10.1080/09513590600629092.
Torréns J.I., Sutton-Tyrrell K., Zhao X., Matthews K., Brockwell S., Sowers M., Santoro N. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women’s Health Across the Nation. Menopause. 2009; 16(2): 257-64
Lizcano F., Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed. Res. Int. 2014; 2014: 757461. https://dx.doi.org/10.1155/2014/757461.
Park S.K., Harlow S.D., Zheng H., Karvonen-Gutierrez C., Thurston R.C., Ruppert K. et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet. Med. 2017; 34(4): 531-8. https://dx.doi.org/10.1111/dme.13301.
Park S.K., Harlow S.D., Zheng H., Karvonen-Gutierrez C., Thurston R.C., Ruppert K. et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet. Med. 2017; 34(4): 531-8. https://dx.doi.org/10.1111/dme.13301.
Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med. 2010; 61: 301-16. https://dx.doi.org/10.1146/annurev.med.080708.082713.
Nelson E.R., Wardell S.E., Jasper J.S., Park S., Suchindran S., Howe M.K. et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013; 342(6162): 1094-8. https://dx.doi.org/10.1126/science.1241908.
Имянитов Е.Н. Биология рака молочной железы. Практическая онкология. 2017; 18(3): 221-31. [Imyanitov E.N. Biology of breast cancer. Practical oncology. 2017; 18 (3): 221-31. (in Russian)].
Simon J.A., Laliberté F., Duh M.S., Pilon D., Kahler K.H., Nyirady J. et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause. 2016; 23(6): 600-10. https://dx.doi.org/10.1097/GME.0000000000000590.
Onstad M.A., Schmandt R., Lu K.H. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J. Clin. Oncol. 2016; 34(35): 4225-30. https://dx.doi.org/10.1200/JCO.2016.69.4638.
Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. 250 с. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2017 (morbidity and mortality). M .: Moscow them. P.A. Herzen branch of the Federal Research Center of Radiology Research Center of the Ministry of Health of Russia; 2018. 250p. (in Russian)].
World Cancer Research Fund/American Institute for Cancer Research: Continuous Update Project Report. Food: nutrition, physical activity, and the prevention of endometrial cancer. 2013. Available at: http://www.dietandcancerreport.org
Roberts H., Hickey M., Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia Cochrane review summary. Maturitas. 2014; 77(1): 4-6. https://dx.doi.org/10.1016/j.maturitas.2013.
Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 2008; 107(1): 103-11.
The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2018; 25(11):1362-1387. doi: 10.1097/GME.0000000000001241 The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2018; 25(11): 1362-1387. https://dx.doi.org/10.1097/GME.0000000000001241.
Юренева С.В. Ведение женщин с менопаузальными расстройствами. Оптимизация рисков МГТ. М.: Умный доктор; 2017. 72 с. [Yureneva S.V. Maintaining women with menopausal disorders. Optimization of MGT risks. M.: Smart doctor; 2017. 72 p. (in Russian)].
Gershuni V., Li Y.R., Williams A.D., So A., Steel L., Carrigan E. et al. Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Res. Treat. 2017; 163(2): 375-81. https://dx.doi.org/10.1007/s10549-017-4192-x.2017;163:375-81.
Printz C. Overweight women may require more frequent mammograms. Cancer. 2018; 124(6): 1099. https://dx.doi.org/10.1002/cncr.31301.
Сметник А.А. Менопаузальная гормонотерапия с дидрогестероном: аспекты эффективности и безопасности ультранизких доз. Медицинский совет. 2017; 2: 92-9. [Smetnik A.A. Menopausal hormone therapy with didrogesterone: aspects of the efficacy and safety of ultra-low doses. Medical advice. 2017; 2: 92-9. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2017-2-92-99.
Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006; 8(5): 538-54.
Mauvais-Jarvis F., Manson J.E., Stevenson J.C., Fonseca V.A. Menopausal hormone therapy and type 2 diabetes prevention: Evidence, mechanisms and clinical implications. Endocr. Rev. 2017; 38(3): 173-88. https://dx.doi.org/10.1210/er.2016-1146.
Marioribanks J., Farquhar C., Roberts H., Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2012; 7: CD004143. https://dx.doi.org/10.1002/14651858.CD004143.pub5.
Mueck A.O., Seeger H., Bühling K.J. Use of dydrogesterone in hormone replacement therapy. Maturitas. 2009; 65(1): 51-60.

Received 12.04.2019

Accepted 19.04.2019

Protasova, Anna E., MD, professor, Department of Oncology, Faculty of Medicine, St. Petersburg State University. 199034, Russia, St. Petersburg,7-9 Universitetskaya Emb.; professor of the Department of Obstetrics and Gynecology, V.A. Almazov National Medical Research Center, Ministry of Health of Russia.
197341, Russia, Moscow, Akkuratova str. 2; professor of the Department of Oncology, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia. 191015, Russia, St Petersburg, Kirochnaya str. 41; head of the Department of Oncology AVA-PETER clinic.
191186, Russia, St. Petersburg, Nevsky prospect, 22-24. Tel.: +79219198424. Е-mail: protasova1966@yandex.ru.
Yureneva, Svetlana V., MD, professor of the Department of Obstetrics and Gynecology, Department of Vocational Education; leading researcher, Department of Gynecological Endocrinology, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry
of Health of Russian Federation; 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79161797400. Е-mail: syureneva@gmail.com
Bairamova, Nurana N., PhD student of the Department of Oncology, Faculty of Medicine, St. Petersburg State University.
199034, Russia, St Petersburg, Universitetskaya Emb. 7-9; obstetrician-gynecologist, oncologist AVA-PETER clinic.
191186, Russia, St. Petersburg, Nevsky prospect, 22-24. Tel.: +79110232111. Е-mail: nurana.bayramova@yandex.ru
Komedina, Veronika I., PhD student of the Department of Gynecological Endocrinology, obstetrician-gynecologist, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of Russian Federation.
117997, Russia, Moscow, Ac. Oparin str. 4. Tel.: +79652146388. Е-mail: komedina.veronika@gmail.com

For citations: Protasova A.E., Yureneva S.V., Bairamova N.N., Komedina V.I. Menopause, obesity, and comorbidity: possibilities of menopausal hormone therapy. Akusherstvo i Ginekologiya/ Obstetrics and Gynecology. 2019; (5): 43-8. (in Russian)
http://dx.doi.org/10.18565/aig.2019.5.43-48

Menopause, obesity, and comorbidity: possibilities of menopausal hormone therapy

Protasova A.E., Yureneva S.V., Bairamova N.N., Komedina V.I.

Keywords

References

About the Authors

Similar Articles